Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
1	18/ES/0029	239530	A subject-, investigator-, and sponsor-blinded, randomized, placebo-controlled, multicenter study to investigate efficacy, safety, and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis	Range Agreed	2	4	Date Agreed	31/07/2021	1	1	31/12/2020	Withdrawn by sponsor	The sponsor closed to recruitment earlier than planned in December following the interim analysis
2	17/NE/0331	229957	A Prospective, Global, Multicentre, Real World Outcome Study of Fenestrated Endovascular Aneurysm Repair using the Fenestrated Anaconda™ device	Range Agreed	1	20	Date Agreed	31/12/2020	6	6	31/12/2020	Recruitment finished	
3	18/LO/0552	242687	Comprehensive Outcomes Registry in Subjects with Epilepsy Treated with Vagus Nerve Stimulation Therapy®	Number Agreed	50	50	Date Agreed	31/12/2020	14	14	31/12/2020	Withdrawn by sponsor	Sponsor closed the study early (from company end) due to commercial realignment of strategy.
4	18/NE/0292	252024	A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study	Number Agreed	4	4	Date Agreed	06/10/2020	4	4	06/10/2020	Recruitment finished	
5	19/LO/0153	259690	A randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, an oral plasma kallikrein inhibitor, in the on-demand treatment of angioedema attacks in adult subjects with hereditary angioedema type I or II	Number Agreed	2	2	Date Agreed	02/10/2020	`	2	02/10/2020	Recruitment finished	
6	18/EM/0193	243749	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVE-CONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)	Number Agreed	2	2	Date Agreed	12/04/2022	1	1	31/12/2020	Recruitment finished	Recruitment finished early nationally
7	19/LO/1500	269558	Basic Evaluation Lead Post-Market Clinical Follow-up (BASIC) Study	Range Agreed	5	20	Date Agreed	31/10/2020	6	6	02/10/2020	Recruitment finished	
8	20/HRA/2191	283184	Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection “ILIAD 7 trial”	Range Agreed	1	3	Date Agreed	25/11/2020	3	3	25/11/2020	Recruitment finished	
9	20/YH/0174	283089	A randomised, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.	Number Agreed	5	5	Date Agreed	18/12/2020	2	2	13/12/2020	Recruitment finished	Recruitment ended early nationally
10	12/YH/0313	106560	A European multi-centre, multi-country, post-authorisation, observational study (registry) of patients with chronic adrenal insufficiency	Range Agreed	200	300	Date Agreed	31/12/2022	271	271	31/10/2020	Recruitment finished	
11	19/WM/0056	256301	Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease	Range Agreed	50	113	Date Agreed	30/08/2021	112	112	27/02/2021	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
12	19/SC/0034	254823	A Phase 3, randomized, double-blind, parallel-group, placebo controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.	Range Agreed	3	6	Date Agreed	10/02/2021	2	2	10/02/2021	Withdrawn by sponsor	Recruitment ended early nationally
13	18/SW/0199	249896	Screening Protocol to Determine Patient Eligibility for Inclusion in AAV Gene Therapy Clinical Trials (ECLIPSE)	Number Agreed	1	1	Date Agreed	30/06/2025	1	1	26/02/2021	Recruitment finished	
14	19/EM/0072	256161	A Long-Term, Randomized, Double-Blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as needed in Response to Symptoms in Symptomatic Adults and Children 4 years of Age or Older with Asthma (MANDALA)	Range Agreed	2	4	Date Agreed	30/01/2021	3	3	30/01/2021	Recruitment finished	
15	19/LO/0357	258769	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy.	Number Agreed	4	4	Date Agreed	31/03/2021	0	0	26/03/2021	Withdrawn by PI	Chronic understaffing due to COVID meant the team were unable to find recruits for the study. The PI took the decision that it wasn't currently safe to continue with the study
16	19/NW/0716	273613	A Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects	Range Agreed	1	5	Date Agreed	10/08/2021	5	5	08/02/2021	Recruitment finished	
17	20/YH/0090	278137	AN OPEN-LABEL,MULTICENTER, ROLLOVER STUDYTO EVALUATE THE SAFETY AND TOLERABILITY OF LONG-TERM ADMINISTRATION OFGANTENERUMABIN PARTICIPANTSWITHALZHEIMER'S DISEASE	Number Agreed	1	1	Date Agreed	31/10/2022	1	1	31/03/2021	Recruitment finished	
18	20/YH/0231	284781	A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA	Number Agreed	2	2	Date Agreed	15/06/2021	2	2	28/02/2021	Recruitment finished	
19	20/HRA/4325	288451	A retrospective study of the characteristics and outcomes of patients with familial chylomicronaemia syndrome treated with volanesorsen in the United Kingdom early access to medicines scheme	Range Agreed	1	2	Date Agreed	11/01/2021	1	1	11/01/2021	Recruitment finished	
20	20/EM/0142	282923	Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment with GSK3228836 in Participants with Chronic Hepatitis B Virus (B-Clear)	Number Agreed	1	1	Date Agreed	27/08/2021	1	1	31/03/2021	Recruitment finished	
21	20/LO/0461	279984	Real-World Anti-VEGF Treatment Experience Study of the Management of Neovascular Age-Related Macular Degeneration in the UK (RATE Study in nAMD)	Range Agreed	15	20	Date Agreed	31/01/2021	17	17	31/01/2021	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
22	16/LO/1637	211258	First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax®-AXL-ADC) in patients with solid tumors	Range Agreed	2	7	Date Agreed	31/10/2020	12	12	31/10/2020	Recruitment finished	
23	19/YH/0301	268446	A Phase 2 Study of ABBV-3067 Alone and in Combination with ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation	Range Agreed	2	4	Date Agreed	31/03/2021	0	0	22/03/2021	Withdrawn by sponsor	M19-530 study is now closed in the UK and Ethics has been notified of Permanent closure. Abbvie will now begin close out activities for all sites that had a finalised contract in place.
24	20/HRA/5205	289098	A PHASE I/II RANDOMIZED, TWO PARTS, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF AN INACTIVATED, ADJUVANTED SARS-COV-2 VIRUS VACCINE CANDIDATE (VLA2001), AGAINST COVID-19 IN HEALTHY INDIVIDUALS	Number Agreed	35	35	Date Agreed	15/01/2021	37	37	15/01/2021	Recruitment finished	
25	19/LO/1986	273932	AMD Barometer - Investigating patient-driven barriers to long-term anti-VEGF treatment adherence in wet AMD.	Number Agreed	9	9	Date Agreed	28/02/2021	9	9	28/02/2021	Recruitment finished	
26	18/SC/0286	246516	A Randomised, Double-blind, Parallel-group, Placebo-controlled, Phase Ia/Ib, Multiple-site Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KL1333 after a Single Oral Dose and Multiple Ascending Oral Doses in Healthy Subjects and Patients with Primary Mitochondrial Disease	Number Agreed	4	4	Date Agreed	30/11/2020	4	4	30/11/2020	Recruitment finished	
27	18/LO/1923	253458	A descriptive non-interventional study to evaluate the use of direct oral anticoagulants in UK clinical practice for patients with a first stroke attributable to nonvalvular atrial fibrillation	Range Agreed	40	50	Date Agreed	30/06/2021	43	43	30/06/2021	Recruitment finished	
28	19/NE/0260	265062	An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy	Number Agreed	5	5	Date Agreed	07/06/2021	5	5	30/04/2021	Recruitment finished	
29	19/EM/0111	262811	CRTH258C2302: An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion (RAVEN)	Number Agreed	4	4	Date Agreed	16/07/2021	4	4	27/05/2021	Recruitment finished	
30	19/NE/0247	259906	A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat (QGC001) Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction after Acute Myocardial Infarction	Range Agreed	5	10	Date Agreed	30/06/2021	4	4	30/06/2021	Recruitment finished	Study recruitment was impacted by COVID-19 and the study team was unable to meet the target of 5

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
31	19/NE/0269	268944	A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)	Number Agreed	3	3	Date Agreed	05/03/2021	3	3	19/02/2021	Recruitment finished	
32	19/SC/0209	263492	A multinational, multicentre, prospective non-interventional study to assess safety and effectiveness of opicapone plus standard of care in elderly patients with Parkinson's Disease	Range Agreed	2	6	Date Agreed	28/04/2021	2	2	22/04/2021	Recruitment finished	
33	20/NE/0032	273692	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER	Range Agreed	2	5	Date Agreed	31/03/2021	0	0	11/03/2021	Recruitment finished	The team failed to recruit any patients. Due to coronavirus the patients were presenting with more advanced disease and poorer performance status than would be eligible for the study
34	20/SC/0031	275229	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis	Range Agreed	1	3	Date Agreed	30/06/2021	0	0	22/04/2021	Withdrawn by sponsor	Global recruitment ended prior to staff capacity issues being resolved at local site
35	20/NW/0383	287807	A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting	Range Agreed	1	10	Date Agreed	07/04/2021	0	0	07/04/2021	Withdrawn by sponsor	After careful consideration, Gilead (Sponsor) made the decision to stop enrollment in study GS-US-540-9012. In light of recent advances, the primary unmet need for patients outside of the hospital setting is for convenient, effective therapies that can be easily administered at home.
36	20/NW/0177	1003027	Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205.	Range Agreed	1	2	Date Agreed	30/04/2021	1	1	30/04/2021	Recruitment finished	
37	20/WA/0203	281292	POLARx Cardiac Cryoablation system Post Market Clinical Follow-up study	Range Agreed	1	10	Date Agreed	30/06/2021	10	10	26/05/2021	Recruitment finished	
38	20/YH/0317	288552	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older	Number Agreed	200	200	Date Agreed	09/04/2021	207	207	09/04/2021	Recruitment finished	
39	21/NW/0125	294164	A RANDOMIZED, OBSERVER-BLIND, CONTROLLED, SUPERIORITY STUDY TO COMPARE THE IMMUNOGENICITY AGAINST COVID-19, OF VLA2001 VACCINE TO AZD1222 VACCINE, IN ADULTS	Range Agreed	120	200	Date Agreed	03/06/2021	134	134	03/06/2021	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
40	19/LO/1753	269460	A phase 2, randomised, double-blind, placebo controlled study to evaluate the safety, efficacy, pharmacodynamics, and pharmacokinetics of SAR339375 for subutaneous injection administered every week in patients with Alport Syndrome	Number Agreed	1	1	Date Agreed	31/05/2021	2	2	31/05/2021	Recruitment finished	
41	18/WM/0038	235048	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional Therapies but Have Not Failed Biologic Therapy.	Number Agreed	1	1	Date Agreed	11/06/2021	0	0	11/06/2021	Recruitment finished	Recruitment closed globally. However, study was very difficult to recruit to due to standard medication being already available
42	18/SW/0159	244565	An International, Prospective Registry Investigating the Natural History of Children with Achondroplasia	Range Agreed	5	10	Date Agreed	30/06/2023	5	5	09/08/2021	Recruitment finished	
43	18/SC/0305	246109	A randomized, open-label, phase II open platform study evaluting the efficacy and safety of novel Spartalizumab (PDR001) combinations in previously treated unresected or metastatic melanoma	Range Agreed	5	12	Date Agreed	05/07/2021	0	0	26/05/2021	Withdrawn by sponsor	Sponsor closed all arms of this study
44	17/EM/0192	223856	A Phase 2, 24-week, Randomized, Double-Blind, Placebo-Controlled, Mulitcenter Study, Followed by a 24-Week Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiopathic Pulmonary Fibrosis	Range Agreed	1	3	Date Agreed	30/11/2021	3	3	23/07/2021	Recruitment finished	
45	19/NM/0442	262204	An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis	Number Agreed	2	2	Date Agreed	30/06/2021	2	2	30/06/2021	Recruitment finished	
46	18/LO/1937	249639	A Phase 1/2 single-arm study evaluating the safety and efficacy of eribulin mesilate in combination with irinotecan in children with refractory or recurrent solid tumors	Range Agreed	1	3	Date Agreed	30/09/2021	2	2	10/06/2021	Recruitment finished	
47	19/EM/0300	267054	Effectiveness of an image analysing algorithm to diagnose non-melanoma skin cancers compared to gold standard histological determination.	Range Agreed	10	50	Date Agreed	30/07/2021	10	10	30/07/2021	Recruitment finished	
48	20/EE/0031	275993	Randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute non-cardioembolic ischemic stroke	Range Agreed	8	10	Date Agreed	02/08/2021	7	7	22/07/2021	Recruitment finished	Global target was hit earlier than expected and the sponsor closed the study to recruitment
49	20/NI/0111	283403	AT100-01: An AAV8 Neutralizing Antibody Seroprevalence Study in Subjects with Late Onset Pompe Disease	Number Agreed	5	5	Date Agreed	01/07/2021	5	5	01/07/2021	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
50	20/EE/0170	1003070	Multicenter, randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction	Number Agreed	10	10	Date Agreed	31/07/2021	7	7	15/07/2021	Recruitment finished	Recruitment ended early nationally after global recruitment was met
51	20/LO/0828	279777	Master protocol of two randomized, double-blind, placebo controlled, multi center, parallel-group studies of dupilumab in patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite the use of H1 antihistamine treatment in patients naïve to omalizumab and in patients who are intolerant or incomplete responders to omalizumab	Number Agreed	1	1	Date Agreed	27/10/2021	0	0	30/09/2021	Withdrawn by sponsor	Due to the pandemic, the UK recruitment was sinigicantly affected and sponsor closed the study earlier than expected
52	20/YH/0178	283168	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety.	Number Agreed	4	4	Date Agreed	31/10/2021	0	0	03/09/2021	Withdrawn by sponsor	Recruitment finished early nationally
53	20/EM/0284	288568	A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment with GSK3228836 followed by Pegylated Interferon Alpha 2a in Participants with Chronic Hepatitis B Virus (B-Together)	Range Agreed	1	2	Date Agreed	31/10/2021	1	1	25/08/2021	Recruitment finished	
54	21/SC/0200	300677	A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Both Previously Vaccinated and Unvaccinated Adults Ages 30 and Above to Determine the Safety and Immunogenicity of AZD2816, a Vaccine for the Prevention of COVID-19 Caused by Variant Strains of SARS-CoV-2	Range Agreed	50	70	Date Agreed	07/09/2021	62	62	07/09/2021	Recruitment finished	